Development of new therapies

EACS recommendations for development of new therapies can be summarized as follows:

• Increase support to academia-initiated clinical trials (including diagnostics, drug development, radiation therapy, associated translational research, surgery and multimodal treatment).
• Encourage and support research in drug repurposing to find new applications of well-established and widely available generic medicines.
• Adopt existing and create new innovative investigator-initiated trial concepts such as Drug Rediscovery Protocol or basket studies, exploring new engagement paradigms with the pharmaceutical industry.
• Support treatment optimization research to identify the optimal dosage and duration of existing treatments, both for the benefit of patients and to guarantee the sustainability of healthcare systems.
• Improve stratification methods of patients using multi-omics, novel complex multilayer biomarkers based on systems biology models.
• Develop methodologies for predicting treatment outcomes (in silico studies).
• Stimulate development and application of new functional and molecular imaging technologies (including radiomics).
• Increase support to already-established multicentre platforms for early drug development.
• Develop new sophisticated in vitro and in vivo functional screening methods (e.g. Interspaced clustered regularly short palindromic repeats/Cas9 based in preclinical models, i.e. Patient-derived xenografts or organoids) to identify new therapeutic paradigms.
• Support the development of academic cell therapy entities (e.g. Chimeric antigen receptor T cells cell production) to boost further innovation in less toxic immunotherapy approaches.
• Promote integration of advanced computational methods (AI, machine learning) with clinical research.
• Structure implementation research in therapeutics to effectively introduce practice-changing therapies.

« Back